Alpine Immune Sciences price target raised to $35 from $26 at Wedbush

Wedbush raised the firm’s price target on Alpine Immune Sciences (ALPN) to $35 from $26 and keeps an Outperform rating on the shares after Vera Therapeutics (VERA) reported updated data from the Phase 2b ORIGIN study evaluating atacicept, a WT- TACI BAFF/APRIL antagonist, in IgAN with follow-up through 72 weeks. The firm sees positive readthrough from these longer term data to Alpine’s povetacicept, as it confirms the potential utility of BAFF/APRIL inhibitors as a disease-modifying therapy with long-term use, the analyst tells investors in a research note.